Saxenda weight loss claims: what the studies actually show
Quick answer
Saxenda (liraglutide 3mg) is a GLP-1 receptor agonist approved for chronic weight management, typically initiated at 0.6mg with weekly dose escalation. The creator appears to be in early dose escalation, where GI side effects including reflux and bloating are most prevalent due to delayed gastric emptying. Reported weight loss of 12kg in 2.5 weeks likely includes a significant component of water and glycogen loss rather than adipose tissue reduction alone.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @burdiexo actually say?
@burdiexo reported losing "12 kilos in a total in two and a half weeks" on Saxenda, finishing her first pen and starting her second. She also described significant side effects, including "a lot of reflux and a lot of bloating," and said she'd learned to avoid spicy foods to manage symptoms. The tone is enthusiastic, personal, and pretty relatable.
This is a classic GLP-1 journey update: big number, real side effects, dietary adjustments. Nothing here sounds fabricated. But the weight figure deserves a closer look, because 12kg in 2.5 weeks is a striking claim, and social media doesn't always distinguish between fat loss and water weight.
Does the science back this up?
Partially. Rapid early weight loss on liraglutide (Saxenda's active ingredient) is real, but 12kg in 2.5 weeks is on the extreme end. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed average weight loss of about 8.4kg over 56 weeks at the full 3mg dose. That's average, not maximum, and it doesn't account for the first few weeks of aggressive water weight loss many users experience when appetite drops sharply.
Water and glycogen depletion can account for 2-5kg in the first week alone when caloric intake drops substantially. So is 12kg biologically plausible? Possibly, if a significant chunk is fluid. Is it 12kg of fat? Almost certainly not. Fat loss at that rate would require a caloric deficit far beyond what's physiologically realistic, roughly 84,000 calories in 17 days.
- Pi-Sunyer et al., 2015 (NEJM): Mean fat mass reduction with liraglutide 3mg was gradual, not frontloaded.
- Gibson et al., 2015 (Obesity Reviews): Early weight loss on caloric restriction is predominantly water and glycogen.
What did they get wrong (or right)?
She got the side effects exactly right. Reflux and bloating are among the most commonly reported GI adverse effects with liraglutide. The SCALE trials consistently showed GI events in 60-70% of participants, particularly in the dose escalation phase. Her observation that dietary changes, specifically cutting spicy food, helped resolve symptoms is consistent with clinical guidance. GPs and dietitians routinely advise low-fat, low-spice diets during GLP-1 initiation.
Where she's misleading, probably without intending to be, is presenting 12kg as a simple, clean result without context. Viewers with different starting weights, doses, or metabolic profiles may expect the same outcome and feel like failures when they don't get it. The number itself isn't wrong, it's just missing the asterisk that early losses are disproportionately fluid, not fat.
She also doesn't mention she's still in dose escalation, which matters. Early Saxenda doses (0.6mg, 1.2mg) are starter doses, not therapeutic doses. Most clinical weight loss occurs at 3mg. Her results may look different once the dose stabilizes.
What should you actually know?
If you're watching this and thinking Saxenda will deliver 12kg in under three weeks, pump the brakes. Clinical trials suggest 5-10% body weight reduction over several months at the full dose, which is meaningful and significant for metabolic health, just not a TikTok highlight reel.
The GI side effects she describes are not a sign something is wrong. They're a known, expected pharmacological response. Liraglutide slows gastric emptying, which causes the bloating and reflux. Eating smaller meals, avoiding high-fat and spicy foods, and staying upright after eating are all evidence-backed ways to reduce these effects, exactly what she figured out through trial and error.
One thing worth adding: Saxenda requires a proper clinical assessment before starting. It's not appropriate for everyone, and the dose escalation schedule exists for a reason. Self-adjusting or skipping steps because results feel slow is a common mistake that worsens side effects without improving outcomes.
- Talk to a prescribing clinician if GI symptoms persist beyond the first few weeks.
- Weigh yourself consistently, same time, same conditions, to reduce noise in the numbers.
- Early dramatic losses almost always slow down. That's normal physiology, not failure.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda weight loss claims: what the studies actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Saxenda weight loss claims: what the studies actually show should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Saxenda (liraglutide 3mg) is a GLP-1 receptor agonist approved for chronic weight management, typically initiated at 0.
FormBlends verdict
Saxenda (liraglutide 3mg) is a GLP-1 receptor agonist approved for chronic weight management, typically initiated at 0.6mg with weekly dose escalation. The creator appears to be in early dose escalation, where GI side effects including reflux and bloating are most prevalent due to delayed gastric emptying. Reported weight loss of 12kg in 2.5 weeks likely includes a significant component of water and glycogen loss rather than adipose tissue reduction alone.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Saxenda (liraglutide 3mg) is a GLP-1 receptor agonist approved for chronic weight management, typically initiated at 0.6mg with weekly dose escalation. The creator appears to be in early dose escalation, where GI side effects including reflux and bloating are most prevalent due to delayed gastric emptying. Reported weight loss of 12kg in 2.5 weeks likely includes a significant component of water and glycogen loss rather than adipose tissue reduction alone.
- Pi-Sunyer et al. (2015, NEJM): Average weight loss on liraglutide 3mg was 8.4kg over 56 weeks, not 12kg in 2.5 weeks.
- Early rapid weight loss on GLP-1 medications is largely water and glycogen depletion, not fat loss, and typically slows significantly after the first few weeks.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Pi-Sunyer et al. (2015, NEJM): Average weight loss on liraglutide 3mg was 8.4kg over 56 weeks, not 12kg in 2.5 weeks.
- Early rapid weight loss on GLP-1 medications is largely water and glycogen depletion, not fat loss, and typically slows significantly after the first few weeks.
- 60-70% of Saxenda users experience GI side effects like reflux and bloating during dose escalation, according to the SCALE trial program.
- Liraglutide slows gastric emptying, which means dietary triggers like spicy or high-fat foods cause more pronounced symptoms than they would off the medication.
- Saxenda starts at 0.6mg and escalates to a therapeutic dose of 3mg. Weight loss results during the titration phase do not represent what to expect long-term.
- Saxenda is a long-term weight management treatment, not a finite course. Stopping it typically results in weight regain without accompanying lifestyle changes.
- Anyone considering Saxenda should be assessed by a qualified clinician. It is not appropriate for all body types, health histories, or medication combinations.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Burdie Lee · TikTok creator
332.6K views on this video
Saxenda Update!! #saxenda #saxendajourney #saxendaweightlossjourney #capcut
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Burdie Lee, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.